The news: Johnson & Johnson is expanding its US manufacturing presence with a $2 billion investment in North Carolina via a partnership with Fujifilm Biotechnologies.

Why it matters: This is the latest Big Pharma financial pledge to boost US drug production as the industry awaits President Trump's tariffs on the sector. For context, Trump threatened an ultra-high, phased-in 250% import tax on the drug industry earlier this month—perhaps as a tactic to secure further US manufacturing commitments.

• 15 leading pharma companies have committed more than $270 billion in US manufacturing and R&D projects over the next 5 to 10 years, per a recent report from JLL. That figure is likely even higher since not all investment plans get their own announcements.
• J&J noted that the passage of Trump’s megabill was also a factor in the company’s latest manufacturing investment, as it provides tax incentives for domestic production.
• J&J announced a $55 billion investment earlier this year and says it has more manufacturing facilities in the US than any other country.
• The FDA recently rolled out a PreCheck initiative, aimed at helping pharma companies build US manufacturing plants more quickly.

Our take: Some US builds have been in the works for years, which means pharma is happy to make this good-faith “concession”—especially after seeing the impact the COVID-19 pandemic had on global supply chains. Even if Trump changes course on tariffs, or if the next administration has a completely different view, pharma companies won’t regret having more production capability in their biggest market.

However, an influx of brand-name drugs made in the US doesn’t mean those medicines will become cheaper for patients here. That’s because pharma companies can generally charge what they want for their blockbuster products (outside of certain drugs under Medicare). Additionally, higher labor costs in the US compared with other countries could drive increases in manufacturers’ list prices.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.